MEDP Medpace Holdings Inc
Price (delayed)
$324.11
Market cap
$9.87B
P/E Ratio
24.82
Dividend/share
N/A
EPS
$13.06
Enterprise value
$9.33B
Medpace is a scientifically-driven, global, full-service clinical contract research organization (CRO) providing Phase I-IV clinical development services to the biotechnology, pharmaceutical and medical device industries. Medpace's mission is to accelerate
Highlights
The net income has increased by 43% YoY and by 11% from the previous quarter
The EPS is up by 42% YoY and by 10% QoQ
Medpace Holdings's equity has increased by 48% YoY but it has decreased by 6% from the previous quarter
Medpace Holdings's quick ratio has increased by 47% YoY but it has decreased by 6% QoQ
Key stats
What are the main financial stats of MEDP
Market
Valuations
Earnings
Shares outstanding
30.47M
Market cap
$9.87B
Enterprise value
$9.33B
Price to earnings (P/E)
24.82
Price to book (P/B)
12.2
Price to sales (P/S)
4.76
EV/EBIT
20.69
EV/EBITDA
18.54
EV/Sales
4.42
Revenue
$2.11B
Gross profit
$656.31M
Operating income
$446.87M
Net income
$404.39M
EBIT
$450.93M
EBITDA
$503.3M
Free cash flow
$572.27M
Per share
Balance sheet
Liquidity
EPS
$13.06
EPS diluted
$12.63
Free cash flow per share
$18.49
Book value per share
$26.56
Revenue per share
$68.13
TBVPS
$45.36
Total assets
$2.1B
Total liabilities
$1.28B
Debt
$126.23M
Equity
$825.55M
Working capital
-$75.32M
Debt to equity
0.15
Current ratio
0.93
Quick ratio
0.87
Net debt/EBITDA
-1.08
Margins
Efficiency
Dividend
EBITDA margin
23.9%
Gross margin
31.1%
Net margin
19.2%
Operating margin
21.2%
Return on assets
20.5%
Return on equity
51.5%
Return on invested capital
N/A
Return on capital employed
45.3%
Return on sales
21.4%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
MEDP stock price
How has the Medpace Holdings stock price performed over time
Intraday
-0.25%
1 week
-0.5%
1 month
-5.34%
1 year
-20.54%
YTD
-2.44%
QTD
-2.44%
Financial performance
How have Medpace Holdings's revenue and profit performed over time
Revenue
$2.11B
Gross profit
$656.31M
Operating income
$446.87M
Net income
$404.39M
Gross margin
31.1%
Net margin
19.2%
The net income has increased by 43% YoY and by 11% from the previous quarter
The operating income has increased by 33% year-on-year and by 9% since the previous quarter
The net margin is up by 28% year-on-year and by 8% since the previous quarter
MEDP's gross profit is up by 25% year-on-year and by 7% since the previous quarter
Growth
What is Medpace Holdings's growth rate over time
Valuation
What is Medpace Holdings stock price valuation
P/E
24.82
P/B
12.2
P/S
4.76
EV/EBIT
20.69
EV/EBITDA
18.54
EV/Sales
4.42
The EPS is up by 42% YoY and by 10% QoQ
The P/E is 24% lower than the last 4 quarters average of 32.7 and 20% lower than the 5-year quarterly average of 31.1
Medpace Holdings's equity has increased by 48% YoY but it has decreased by 6% from the previous quarter
MEDP's price to book (P/B) is 18% lower than its last 4 quarters average of 14.9 but 3.6% higher than its 5-year quarterly average of 11.8
MEDP's price to sales (P/S) is 15% less than its last 4 quarters average of 5.6 and 2.7% less than its 5-year quarterly average of 4.9
MEDP's revenue is up by 12% year-on-year
Efficiency
How efficient is Medpace Holdings business performance
The company's return on equity fell by 20% YoY
The ROS is up by 20% YoY and by 7% QoQ
Medpace Holdings's return on assets has increased by 8% YoY and by 4.6% QoQ
Dividends
What is MEDP's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for MEDP.
Financial health
How did Medpace Holdings financials performed over time
The company's total assets is 65% higher than its total liabilities
Medpace Holdings's quick ratio has increased by 47% YoY but it has decreased by 6% QoQ
Medpace Holdings's current ratio has increased by 45% YoY but it has decreased by 6% QoQ
The debt is 85% smaller than the equity
Medpace Holdings's equity has increased by 48% YoY but it has decreased by 6% from the previous quarter
MEDP's debt to equity is down by 40% year-on-year
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.